PDCD1 and neoplasm: As PD-1 is the most extensively studied immune checkpoints, several fusion proteins containing antibodies against PD-1 and IL-2 variant have been produced for tumor immunotherapy, which have exhibited significantly improved antitumor effects in preclinical tests (Piper et al., 2023, Tichet et al., 2023).